WP8 - Clinical validation (randomized trials & interventions)
WP leaders
Paul Franks and Gustav Smith
Objectives
- To provide a platform and accumulated expertise for proof of concept trials originated from discoveries within LUDC
- To provide a platform and accumulated expertise for prevention and intervention clinical trials, including evalutation of new therapies and life-style interventions
- To generate new samples for the discovery of dynamic biomarkers (i.e. a biomarker that capture the drug response and allows for accurate estimations of long-term drug efficacy)
Press releases
- New study on personalized type 2 diabetes treatment launched, 2020 https://www.lunduniversity.lu.se/article/new-study-personalized-type-2-diabetes-treatment-launched
- Roadmap for precision medicine in diabetes care, 2020 https://www.lunduniversity.lu.se/article/roadmap-precision-medicine-diabetes-care
- Lund University to participate in international obesity research project, 2020 https://www.lunduniversity.lu.se/article/lund-university-participate-international-obesity-research-project
- Broccoli in focus when new substance against diabetes has been identified, 2017 https://www.lunduniversity.lu.se/article/broccoli-focus-when-new-substance-against-diabetes-has-been-identified
News
- Screening reveals early nerve damage (Eero Lindholm, 2020): https://www.ludc.lu.se/article/screening-reveals-early-nerve-damage
Selected publications
- Axelsson AS et al. Sulforaphane reduces hepatic glucose production and improves glucose control in patients with type 2 diabetes. Sci Transl Med 2017 https://pubmed.ncbi.nlm.nih.gov/28615356/